Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could stem cells help breathe easier? new trial tests PROCHYMAL for COPD

NCT ID NCT00683722

Disease control Sponsor: Mesoblast, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether infusions of PROCHYMAL, a stem cell product, are safe and can help people with moderate to severe COPD. 62 participants received either stem cells or a placebo. The main goal was to check for side effects, and researchers also looked at changes in lung function over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PROCHYMAL (adult stem cells from bone marrow)
What this could lead to
If it works, this could point toward a new way to treat COPD by reducing inflammation and possibly improving lung function.
What could go wrong
This is an early phase 2 trial with only 62 people, so results may not apply to everyone. Stem cell treatments can have unknown long-term risks, and the placebo group may show similar benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

62 people

The number who actually took part.

Started

Mar 2008

Finished

Aug 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have a diagnosis of moderate or severe COPD. * Participant must have a post-bronchodilator FEV1/forced vital capacity (FVC) ratio \< 0.7. * Participant must have a post-bronchodilator FEV1 % predicted value ≥ 30% and \< 70%. * Participant must be between 40 and 80 years of age, of either sex, and of any race. * Participant must be a current or ex-smoker, with a cigarette smoking history of ≥ 10 years or \> 10 pack-years. Exclusion Criteria: * Participant has been diagnosed with asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer). * Participant has been diagnosed with α1-antitrypsin deficiency. * Participant has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb). * Participant has active infection. * Participant has had a significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening. * The participant with clinically relevant uncontrolled medical condition not associated with COPD. * Participant has documented history of uncontrolled heart failure. * Participant has pulmonary hypertension due to left heart condition. * Participant has atrial fibrillation or significant congenital heart defect/disease. * Participant has initiated pulmonary rehabilitation within 3 months of screening. * Participant is allergic to bovine or porcine products. * Participant has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years. * Participant has a life expectancy of \< 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic bronchitis chronic obstructive pulmonary disease COPD, severe early onset pulmonary emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic bronchitis Pulmonary disease, chronic obstructive Pulmonary emphysema

Contacts and locations

Locations

  • American Health Research

    Charlotte, North Carolina, 28207, United States

  • David Geffen School of Medicine at UCLA

    Los Angeles, California, 90095, United States

  • Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center

    Torrance, California, 90502, United States

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • Upstate Pharmaceutical Research

    Greenville, South Carolina, 29615, United States

  • Vermont Lung Center, University of Vermont

    Burlington, Vermont, 05446, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.